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Phage display is a convenient method to select proteins of interest based on binding 
affinity. The Barker lab recently used this technology to discover an antibody fragment 
(scFv), termed H5, capable of selectively binding to the integrin binding domain of 
fibronectin (Fn) under a strained configuration, typically due to forces exerted on the 
extracellular matrix (ECM) by cells. 
Large scale production of H5 scFv is hindered by non-optimized codons and 
suspected protein toxicity, since the E. coli strain producing the protein grew poorly at 
normal temperatures. Moreover, the transfected vector containing H5, pIT2, appeared to 
be degraded in consecutively selected bacterial cultures, as suggested by the isolation of 
significantly shorter than expect plasmids. 
After significant effort, reconstruction of the pIT2 vector sequence was 
accomplished from multiple colonies and cross referencing with the provided anti-
ubiquitin scFv antibody fragment, and the complete DNA sequence of H5 was recovered. 
The sequence was codon optimized for expression in an E. coli strain engineered for high 
levels of scFv production. Furthermore, the H5 DNA was recombined with error prone 
PCR, to generate a library of random mutants, which was transformed into a stable, E. coli 
strain. This library will be panned on the targets again through phage display in order to 
find an improved version of H5, defined by more selective binding to the extended 







IDIOPATHIC PULMONARY FIBROSIS 
 
Idiopathic pulmonary fibrosis (IPF) is the most common form of interstitial lung 
disease. Incidence of IPF in the US is deemed to be 20 to 60 cases per a hundred thousand 
people, to which 14000 to 34000 more cases are diagnosed each year (Álvarez, Levine, & 
Rojas, 2015). The disease typically affects older people, preferentially male (1.5 to 1 ratio 
with females), with 66 being the median age of diagnosis (King Jr, Pardo, & Selman, 2011).  
IPF is a scarring, progressive pathology with a 5-year survival rate of 20% (Kreuter et al., 
2015). Early symptoms of the disease include breathlessness upon exertion and dry cough 
that interferes with the patient’s daily activities (Meltzer & Noble, 2008). Given the 
patients age, these traits are often attributed to aging or other syndromes, thus delaying the 
diagnosis. Clinically, IPF is characterized by inspiratory crackles during auscultation, often 
along with clubbing. Patients also suffer from decreased forced vital capacity and forced 
expiratory volume, coupled with impaired gas exchange, which can be demonstrated by 
measuring the diffusion capacity (Meltzer & Noble, 2008). 
Guidelines for diagnosis from the American Thoracic and European Respiratory 
Societies (ATS/ERS) recommend a combined clinical exam, computer tomography and 
lung biopsy. Typical patterns of fibrosis visible through high resolution computer 
tomography consist of evident bilateral, peripheral and subpleural reticular infiltrates. 
Often, the presence of advanced fibrosis is indicated by honeycomb changes and traction 
bronchiectasis (Meltzer & Noble, 2008). Lung biopsy is still considered the gold standard 
for IPF diagnosis, because it allows detection of histopathological lesions and structures 
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like fibroblastic foci, which are pale-staining whirls of loose extracellular matrix molecules 
(mostly collagen), interspersed with numerous fibroblasts (Meltzer & Noble, 2008). 
However, the high degree of spatial heterogeneity of fibrotic tissue, as shown in Figure 1, 
hinders the overall usefulness of biopsies when not assisted by imaging techniques. The 
current Clinical Practice Guideline on management of IPF recommends several 
pharmacological treatments such as pirfenidone, a downregulator of key profibrotic 
factors, and nintedanib, an inhibitor for several tyrosine kinases. While the latter two 
compounds showed most promise in recent clinical trials, none of them represent a cure 
for IPF since patients continue to degenerate despite such treatments (Kreuter et al., 2015). 
Because today IPF is still an incurable disease outside of a lung transplant, it is necessary 
to extensively investigate the mechanisms behind the etiology and progression of IPF, in 




Figure 1: Tomography scan showing classic features of IPF. Arrowheads illustrate honeycomb structural 
changes, while arrow shows traction bronchiectasis. (Meltzer & Noble, 2008). 
 
A major pathological process in IPF is the deposition of provisional matrix, made 
up by fibrinogen and fibronectin (Fn), in the alveolar spaces following lung injury. 
Evidence suggests that this provisional matrix could stimulate epithelial to mesenchymal 
transition even without TGFβ (King Jr et al., 2011). Persistence of such matrix leads to the 
differentiation of fibroblasts to myofibroblasts which organize in fibroblastic foci and 
release excessive amounts of ECM (King Jr et al., 2011). Fibroblasts that have 
differentiated down a contractile, myofibroblastic pathway are known to exhibit significant 
contractile force. Such cell-derived forces are capable of stressing the surrounding ECM, 
leading to increased microenvironmental stiffness, including Fn strain (Brown, Fiore, 
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Sulchek, & Barker, 2013). Myofibroblast presence and the related stress increase could 
become a significant IPF marker to facilitate diagnosis. 
Our lab and others have shown that fibrotic lung ECM is significantly stiffer 
compared to normal ECM, using atomic force spectroscopy (Brown et al., 2013). 
Moreover, recent investigations have suggested that reduced lung compliance is associated 
with increased integrin α5β1 mediated Fn deposition and basement membrane matrix 
assembly (Bennett et al., 2013) Thus, it is hypothesized that the mechanical changes to the 
Fn matrix may be a molecular signature for progression of the disease. 
The severity of IPF and the need for a quicker diagnosis warrant further research 
on developing potentially non-invasive probes to detect biophysical changes of Fn and 
disease progression. 
 
RELEVANCY OF FIBRONECTIN CONFORMATION 
 
The ECM of various tissues have different composition and organization, despite 
the same basic components being water, polysaccharides and proteins. Fibrous ECM 
proteins form three-dimensional scaffolds that support cells and influence tissue 
morphology (Frantz, Stewart, & Weaver, 2010). Rigidity of the ECM scaffold acts as a 
signal to the surrounding cells through to mechanotransduction (Mochitate, Pawelek, & 
Grinnell, 1991). Among ECM fibular proteins, Fn is of particular interest because of its 
presence in the provisional matrix of tissues undergoing regenerations, its effects on cell 
behavior through specific integrin interactions, its high degree of spatial flexibility, and 




Figure 2: Modular structure of fibronectin subunit (Bachman, Nicosia, Dysart, & Barker, 2015). 
 
Fn is a glycoprotein formed by two identical subunits weighing 220 KDa each and 
are covalently linked by a couple of disulfide bonds towards the C-termini. A single subunit 
is composed by three repeated types of domain: Type I, Type II and Type III (Bachman et 
al., 2015). While the former two types are set in a rigid conformation because of internal 
disulfide bonds, the latter type completely lacks this feature. Specifically, Type III domains 
are made up by antiparallel β sheets connected by flexible loops and held together just by 
hydrogen bonds (Gao et al., 2003; Main, Harvey, Baron, Boyd, & Campbell, 1992). 
Consequently, Type III repeats are highly susceptible to unfolding due to force (Krammer, 
Craig, Thomas, Schulten, & Vogel, 2002).  
10III was ascertained to be the Type III repeat with the lowest threshold for 
deformation with both steer molecular dynamics and atomic force microscopy (“The 
Mechanical Hierarchies of Fibronectin Observed with Single-molecule AFM,” n.d.), 
implying that it will be one of the first domains to unfold under force. 
Fn 10th Type III (10III) repeat possess a canonical arginine, glycine, aspartic acid, 
serine (RGDS) peptide sequence, which acts as a cell binding site, while the 9th Type III 
repeat contain a synergistic site that provides domain recognition and mediates cell 
adhesion and cytoskeletal organization (Dufour et al., 1988; Pierschbacher & Ruoslahti, 
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1984). The proximity of these two sites has been the object of several studies because of 
the importance of physical coupling between extracellular and integrin selectivity. Indeed, 
RGD peptides by themselves are not enough to select specific integrin binding, since they 
are ubiquitous in other ECM proteins and ligate several kinds of integrin (Pierschbacher & 
Ruoslahti, 1984). For example, integrin α5β1 binding requires RGD and the 
aforementioned synergy sequence (PSHRN) on the 9th Type III repeat (Mardon & Grant, 
1994) to be about 32 Å apart. However, when a force of just 10 pN is applied, the 10th 
repeat partially unfolds and the RGD domain is removed from the synergy site, so that the 
distance between the two increases to 55 Å (Krammer et al., 2002). This 23 Å change 
greatly reduces α5β1 binding (Stabenfeldt, Brown, & Barker, 2010). Fibroblasts lower 
bound for mechanical force exerted is in the tens of nN (Tan et al., 2003). Conversely, 
integrins that do not coordinate binding with the synergy site, such as αvβ3, are not affected 




Figure 3: Steered molecular dynamics of simulation of early stages of 10III unfolding under force. RGD 
loop is shown in red between the F and G strands. As the G strand of 10III (shown in (A)) is pulled (B), the 
RGD loop is brought closer to the bulk of the module (C) (Bachman et al., 2015). 
 
Thanks to its binding sites for integrins, ECM proteins, growth factors and other Fn 
molecules, Fn is associated with coordinated tissue behaviors, including morphogenesis, 
wound healing (Pankov & Yamada, 2002), and even pathologies like IPF in vivo. This led 
to hypothesize that the force sensitivity of Fn could be considered a mechanism of 
mechanosensitive control of ligand recognition (Krammer, Lu, Isralewitz, Schulten, & 
Vogel, 1999). To investigate this mechanism, recombinant 9III and 10III were expressed 
as single Fn fragments for in vivo integrin targeting experiments. Furthermore, a leucine to 
proline modified version, Fn 9*10, was developed to provide greater stability to RGD and 
the synergy site (Krammer et al., 2002). This new fragment offered more clustering of α5 
integrins than compared with wild type Fn. This and other assays suggest that integrin 
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engagement selectivity affects disparaged cells responses. On the other hand, recombinant 
9III and 10III were expressed with the addition of short flexible linkers, which are mainly 
made up by a varying of consecutive glycine residues, in order to provide tensile  character 
and increase distance between the synergistic sites (Grant, Spitzfaden, Altroff, Campbell, 
& Mardon, 1997). Our lab has successfully employed a similar Fn fragment, dubbed 4G 
whose linker is comprised by 4 glycine resisdues. Fn conformation affects the ability of 
cells to migrate on or assemble a Fn matrix, when only αv integrins are expressed, while 
those two functions are recovered upon the reintroduction of α5 subunits (β1 as second 
integrin subunit in both cases) (Zhang et al., 1993). The action of α5β1 in Zhang et al. assay 
mirrors the effects on lung compliance in IPF by Fn and the same integrin in wild type 
cells. As previously stated, Fn plays a major role in wound healing and the provisional 
matrix. It is theorized that the integrin specificity mechanism would play a role in that too. 
While the Fn matrix mimicking constructs by the Hocking group (Roy & Hocking, 2012) 
showed improved wound repair, the contribution of integrins α5β1 and αvβ3 could not be 
conclusively discerned. Also, integrin specific Fn like constructs on polyacrylamide (PAA) 
gels of varying stiffness managed to mask the stiffness induced epithelial-to-mesenchymal 
transition, as long as the α5 and α3 subunits were engaged.  
In the end, Fn conformation has far reaching impact beyond the mechanical 
properties as a substrate or ECM component thanks to its integrin specificity switch. 
Nonetheless, new probes are needed to fully understand the complexities of Fn and its 
effects on physiological process and pathologies. Specifically, while sufficient in vitro 
evidence for the unfolding of the Fn domains exists, a reliable method to image 




PHAGE DISPLAY TECHNOLOGY 
 
Phage display technology was first reported on by Smith in 1985 (Smith, 1985) 
when the technique was employed only for the selection of simple peptides. As the 
technology was refined, application such as pathogen detection (Petrenko & Vodyanoy, 
2003), enzyme activity enhancement by randomly altering the active site (Clark & March, 
2006; Fernandez-Gacio, Uguen, & Fastrez, 2003), but phage display rose to prominence 
because of its simplicity in monovalent antibody fragment (Fab) production compared to 
monoclonal antibody production in hybridomas (Ascione et al., 2005). 
Arguably, the most lucrative product of this approach is Adalimubab (marketed as 
Humira and approved only in 2008), a full size antibody, which is a rheumatoid arthritis 
drug that was derived through phage display. This drug acts by binding TNFα, preventing 
the interaction with its receptor, thus blocking the inflammatory response of autoimmune 
diseases (Humira, 2016). 
Intact antibodies like immunoglobulins gamma (IgG) are bivalent, with high 
functional affinity and high retention times. The presence of the fixed chain (Fc) domain, 
however, can lead to undesirable effects in certain applications such as poor contrast in 
imaging or the triggering of cytokine release in vitro and especially in vivo. These issues 
were solved by engineering monovalent fragments. Single chain antibody fragments 
(scFv), Fab, single variable VH and VL domains all belong to the above category (Holliger 
& Hudson, 2005).  
The advantages of scFv over intact antibodies do not end with the lack of the Fc 
segment. Because this antibody format is made up by the VH and VL domains joined by a 
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flexible linker portion, it enables targeting of cryptic epitopes because of their reduced size 
(Ward, Güssow, Griffiths, Jones, & Winter, 1989). For example, several viruses have their 
target receptor binding domain inside narrow cavities of their surface antigens, making 
them inaccessible to intact antibodies. Despite not being the ideal antibody fragments for 
in vivo tumor targeting due to their rapid clearance and poor retention due to the 
monovalent binding capacity and size, scFv provide high specificity to target traditionally 
inaccessible binding sites, such as G protein receptors, enzyme active sites and cryptic 
proteins sites (Holliger & Hudson, 2005). 
Thanks to the discovery of high affinity single V-like domain in camelids and 
sharks (Dooley & Flajnik, 2005; Genst et al., 2004), in vivo viable human single domains 
have been designed and made into libraries after addressing the issues with stability, 
solubility, resistance to aggregation (Jespers, Schon, James, Veprintsev, & Winter, 2004). 
 
Figure 4: Schematic representation of different antibody formats, showing intact ‘classic’ IgG molecules 
alongside camelid VhH-Ig and shark Ig-NAR immunoglobulins. Camelid VhH-Ig and shark Ig-NARs are 
unusual immunoglobulin -like structures comprising a homodimeric pair of two chains of V-like and  C-like 
domains (neither has a light chain), in which the displayed V domains bind the target independently. Shark 
Ig-NARs comprise a homodimer of one variable domain (V-NAR) and five C-like constant domains (C-
NAR). A variety of antibody fragments are depicted, including Fab, scFv, single-domain V H , VhH and  V-
NAR and multimeric formats, such as minibodies, bis-scFv, diabodies, triabodies, tetrabodies and chemically 




Phage display is considered ideal for selection of scFv for other characteristics as 
well (Packer & Liu, 2015). Firstly, it offers a covalent linkage between genotype and 
phenotype of the screened peptide, allows library sizes of 1010 (Clackson, Hoogenboom, 
Griffiths, & Winter, 1991), focuses on binding interactions, and the fragments can be 
usually expressed in the periplasmic space of a bacteria like E. coli with little to no 
difficulty. The technique is also accessible once phage libraries are created or purchased. 
Typically, antibody repertoires are fabricated by ligating the VH and VL PCR products, then 
cloned into a display vector in order to fuse the protein of interest with a phage coat protein, 
usually gene III (gIII). Certain phage displays formats, denominated phagemid, have a 
vector that does not encode all the genes necessary for phage replication ensuing infection. 
Thus, a helper phage is used to infect E. coli cells that have been transformed with the 
incomplete vector (Hammers & Stanley, 2014). Once produced from the libraries, phages 
are incubated with antigen, oversampling the antibody repertoires. After incubation with 
antigen and stringent washes, phages are eluted by incubation with trypsin protease. This 
step will elute phage by cutting the c-myc tag between antibody fragment and the phage 
gIII protein. It will also remove background infectivity originating from gene III protein of 
the trypsin sensitive KM13 helper phage, since the gIII protein originating from the 
repertoire phagemid is trypsin-resistant. The eluted phage is then used to infect E. coli 
bacteria and titres are determined by plating of dilution series. For subsequent rounds of 
selections, colonies from the first round are scraped from agar plates and phages are 
produced in liquid culture, PEG purified and selected by binding to antigen. After three 
rounds of selection, individual clones are isolated, grown overnight and soluble fragments 
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are produced in a 96-well format. Finally, antigen-specific clones are identified by ELISA 
(C. M. Y. Lee, Iorno, Sierro, & Christ, 2007). 
Following a similar phage display protocol, the Barker lab has successfully 
developed high binding affinity and highly selective scFv with potential for several 
applications in the study of integrin binding to Fn and IPF mechanisms. The 4G and 9*10 
described earlier were used as epitopes to model the molecular scale conformational 
spacing between the PHSRN and RGD sites. By performing phage display and selection 
using Tomlinson I + J antibody libraries, the isolated scFv antibodies demonstrated 
specificity in binding to the 4G and 9*10 fragments in an ELISA assay, which represent a 
“stretched” and a “relaxed” conformations respectively. After surface plasmon resonance 
(SPR) analysis, the KD for the stretched state was found to be 16 nM, while the KD for the 
relaxed state was 107 nM, making the selected scFv, dubbed H5, bind preferentially to the 
stretched configuration of the Fn fragment, as intended (unpublished data). 
 
ISSUES WITH PROTEIN EXPRESSION IN E. COLI 
 
E. coli has been used as a host for recombinant protein production, including 
immunoglobulin fragments, because of its advantages over mammalian cells. This Gram 
negative bacteria can produce the target protein in large quantities, grows much faster than 
other hosts and transformation with plasmids is simple and requires small amounts of DNA 
(Verma, Boleti, & George, 1998). For the above reasons, E. coli enables inexpensive 
protein production with a quick turnaround time as well. There exist categories of proteins 
that cannot be synthesized in bacteria, such as glycosylated proteins, thus excluding full 
immunoglobulins from this expression system. 
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 Recombinant antibody fragments expressed in the cytoplasm form insoluble 
inclusion bodies, mainly because of the relatively reductive environment there. Aggregates 
are often caused by interactions with misfolded proteins. After harvesting the target 
protein, several downstream processing strategies are available to promote the correct 
refolding of the fragment, which involve forming the proper disulfide bonds, if any (Verma 
et al., 1998). Since scFv contain 2 disulfide bonds, a large investment of time and effort 
would become necessary to reform the correct combination of sulfide bonds. The more 
disulfide bonds are present in a protein, the higher the number of possible combinations. 
For two of such bonds, there would be three combinations, implying that if the bonds 
formed randomly, only one third of the refolded product would possess the correct tertiary 
structure (Jaenicke, 1991). An alternative approach to this ordeal involves using a leader 
sequence to direct the antibody fragment into E. coli periplasmic space. The space between 
the inner and outer membranes of Gram negative bacteria is more oxidizing compared to 
the cytoplasm, contains chaperonin equivalents and disulfide isomerases (Skerra & 
Pluckthun, 1988). The pelB leader sequence at the N terminus, which is cleaved by signal 
peptidase in the periplasm, has been used successfully for decades for this purpose (Ferenci 
& Silhavy, 1987; Lei, Lin, Wang, Callaway, & Wilcox, 1987). Other signal peptides are 
available for the same application and are reviewed elsewhere (Choi & Lee, 2004; 
Mergulhão, Summers, & Monteiro, 2005). Osmotic shocks or cell wall permeabilization 
avoids the need for cell lysis while allowing secretion of the product of interest in the 
culture medium (Shokri, Sandén, & Larsson, n.d.).  
Even when feasible, optimizing antibody fragment production in E. coli is no small 
feat. Choosing the most appropriate strain, promoter and vector are decisions to be made 
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before any expression attempt. Arguably, the most common strain used for protein 
expression is BL21 (DE3), since it lacks Lon protease (Gottesman, 1996) and outer 
membrane protease OmpT (Grodberg & Dunn, 1988), both of which would cause 
degradation of the foreign protein being expressed. Moreover, plasmid loss is prevented 
because of the hsdSB mutation in the parental strain. Other derivative strains from BL21 
offer additional features, such as T7 RNA polymerase under the prophage λDE3, which 
favor certain applications (Rosano & Ceccarelli, 2014).  
The role of promoters is to control the expression of the protein of interest. Good 
promoter attributes include low basal expression, strong expression post induction, 
transferable to other E. coli strains and rely on a convenient induction mechanism. 
Moreover, it should be independent from the growth medium (Terpe, 2006). The lac 
promoter was among the first studied and used as the basis of subsequent iterations, like 
the tac and trc. Specifically, lac promoter is weak even after induction and “leaky” 
(relatively high levels of basal expression). While these traits make it hardly usable for 
large scale and high level expression, they represent an advantage for the production of 
proteins that are toxic to the host, as is often the case with scFv. While the above promoters 
are induced by isopropyl β-D-1-thiogalactopyranoside (IPTG), they are susceptible to the 
metabolic state, manifested by the cytoplasmic level of cAMP. In order to solve this issues, 
the T7 RNA polymerase system was devised (Terpe, 2006). This polymerase transcribes 
DNA sequences up to five times faster than the native RNA polymerase and is expressed 
under a different promoter in the BL21 DE3 strain, which enables strong induction of T7 
with IPTG despite the presence of glucose and independently of cAMP levels (Grossman, 
Kawasaki, Punreddy, & Osburne, 1998).  
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The vector choice impacts multiple aspects of the expression system. First, it 
contains the replicon, an origin of replication and its cis-acting control elements, which 
controls the copy number (Solar, Giraldo, Ruiz-Echevarría, Espinosa, & Díaz-Orejas, 
1998). While it is intuitive to correlate a high plasmid number with high levels of protein 
production, high copy number plasmids risk causing a metabolic burden on the host. This 
adverse effect leads to plasmid instability and decrease in protein producing bacteria 
(Bentley, Mirjalili, Andersen, Davis, & Kompala, 1990; Birnbaum & Bailey, 1991). 
Vectors with wild type ColE1 origin oscillate between 15 and 20 copies per cell (C. Lee, 
Kim, Shin, & Hwang, 2006), while vectors under ColE1 derivatives range from 15-60 to 
500-700 copies  (Bolivar et al., 1977; Minton, 1984). Additionally, vectors define the 
selection marker to keep plasmid-free cells from growing. Antibiotic resistance genes are 
thus included in the vector backbone. Ampicillin is one of the most common antibiotic 
used, despite potential for complete depletion in the growth medium due to continuous 
secretion of β-lactamase (Korpimäki, Kurittu, & Karp, 2003). To obviate this issue, and to 
allow selection for two different plasmids at once, several other markers are available, such 
as chloramphenicol and kanamycin. Alternatively, semi-synthetic penicillins have been 
developed in order to be used in the medium in place of ampicillin. Carbenicillin is one of 
these compounds, boasting improved stability to temperature, pH conditions and enzymatic 
degradations (“Ampicillin vs_ Carbenicillin.pdf,” n.d.).  
Careful planning of an expression system tailored for the protein of interest is no 
guarantee for high level expression. Issues related to the target protein alone can hinder or 
even prevent production unless specific measures are taken, since no or low level 
expression of recombinant protein is likely due to protein toxicity. Unwanted interactions 
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with homeostasis and normal proliferation of the host slows down the growth rate, leading 
to a lower final cell density (Dong, Nilsson, & Kurland, 1995). If the deleterious effects 
are noticeable even before induction, it could prove beneficial to switch to a promoter that 
offers tighter regulations, such as the araBAD or T7 in conjunction with a host expressing 
T7 lysozyme, a natural inhibitor of T7 RNA polymerase. If changing promoter is not an 
option, using media supplemented with glucose as a source of carbon can be effective for 
the lac family of promoters, in order to avoid the inducer (Studier, 2005). If the toxic effects 
are noticeable only after induction, tunable promoters should be used or a new host like 
C41(DE3) or C43(DE3) should be considered. Both strains lead to higher level expression 
of proteins considered highly toxic in BL21 DE3, however C43(DE3) offers better result 
and favors plasmid stability (lack of plasmid degradation) after induction when compared 
to its cognate strain (Dumon-Seignovert, Cariot, & Vuillard, 2004). Culture temperature 
can also play a factor, since lowering it from 37°C reduces the potential for inclusion bodies 
and aggregation of the target protein and can reduce the plasmid copy number (Saida, Uzan, 
Odaert, & Bontems, 2006).  
If host growth were unaffected, but the protein production was still lackluster, 
toxicity can be excluded and the investigation should focus on the DNA sequence codon 
bias. Theoretically, satisfactory protein expression could be easily achieved by codon 
optimizing the insert. However, there are two opposing school of thoughts on the approach 
to follow: one focuses on imitating native highly expressed genes, according to the Codon 
Adoption Index (CAI), with some consideration for mRNA secondary structure (Sharp & 
Li, 1987); the other prefers usage of rare codons that correspond to higher charging tRNA 
levels during host starvation (Elf, Nilsson, Tenson, & Ehrenberg, 2003; Welch et al., 2009). 
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The strategies outlined above informed the methods and approaches presented in 
this work. Evidence suggests that large scale production of H5 scFv is hindered by non-
optimized codons and suspected protein toxicity, since the E. coli strain producing the 
protein grew poorly at typical temperatures (37 °C). Moreover, the transfected vector 
containing H5, pIT2, appeared to be degraded in consecutively selected bacterial cultures, 
as suggested by the isolation of significantly shorter than expect plasmids. The following 
chapter covers the process that, after significant effort, accomplished the reconstruction of 





RECOVERING THE H5 SEQUENCE 
 
The Barker lab isolated the H5 scFv antibody through phage display from the 
Tomlinson I + J libraries, developed by Greg Winter’s group and distributed by 
Lifesciences. Despite providing the primers to sequence the scFv inserts, the exact 
sequence of the pIT2 vector was not made available besides the map reported in Figure 
XX. This piece of information was used to infer the DNA sequence of pIT2 in order to 
devise better primers and formulate a starting consensus sequence after the provided 
sequencing primers did not provide satisfactory results. The newly designed primers 
allowed amplification of the insert DNA of both H5 and the anti-ubiquitin scFv, provided 
with the libraries as a positive control during the phage display process. The PCR products 
of both scFv were sequenced, thus enabling the reconstruction of H5. 
Secondly, the hypothesized pIT2 sequence was investigated and confirmed by 
designing seven sequencing primers pairs that framed roughly 700 bp sections with 100 bp 






Figure 5: Map of pIT2 vector (Lifesciences). The pelB leader enables secretion of the scFv into the 





 HB2151 E. coli cells expected to contain H5 and the pIT2 vector that were 
miniprepped by using a spin column kit (Qiagen) attempt to retrieve the H5 sequence. All 
PCR reactions contained the following mixture: 10 µL of 5X GC buffer (NEB), 1 µL of 
dNTP (10 mM solution, NEB), 1 µL of DMSO (NEB), 0.6 µL of Phusion polymerase 
(NEB), 7.5 µL of each primer (2 µM solution in EB buffer, primers purchased from IDT). 
All reactions included 5 µL of the DNA template and were topped off with DI water to 50 
µL. The template solution was prepared from and diluted to 20 ng/ µL.  
The reaction mixtures were cycled on a BioRad Dyad thermocycler according to 
the following protocol. Denaturation took place at 98 °C for 10 seconds, followed by 
annealing at 75 °C for 30 seconds and extension at 72 °C for 5 minutes, repeated for 30 
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times. The cycles were preceded by holding the samples at 98 °C at the start for 30 seconds 
and a final extension step at 72°C for 5 minutes. 
 
Table 1: Primers used for PCR reactions and sequencing of H5 and pIT2 vector. All primers were purchased 
from IDT. 
Name  Description Sequence 
118 118SEQ/pIT2/pHEN CTATGCGGCCCCATTCA 
119 119SEQ/pIT2/link seq CGACCCGCCACCGCCGCTG 
133 133SP/pIT2/LMB3 CAGGAAACAGCTATGAC 
141 141SP/pIT2H5/Vl CGAAAACTGCTGATAATTTTGACTACTG 
362 362 SEQ/pSB1C3/BB_VF2 CCACCTGACGTCTAAGAAAC 
363 363 SEQ/pSB1C3/BB_VR GTATTACCGCCTTTGAGTGA 
665 665 pIT2 + H5 sequencing primer 1327-2081 Forward GTAGCACCGCCTACATACCT 
666 666 pIT2 + H5 sequencing primer 1327-2081 Reverse CACAACATACGAGCCGGAAG 
667 667 pIT2 + H5 sequencing primer 2944-3672 Forward AAGGTGGAAATCAAACGGGC 
668 668 pIT2 + H5 sequencing primer 2944-3672 Reverse TTGAGGCAGGTCAGACGATT 
669 669 pIT2 + H5 sequencing primer 2442-3180 Forward GTTCACCACCTCCAGAGACA 
670 670 pIT2 + H5 sequencing primer 2442-3180 Reverse ACCAGTACAAACCACAACGC 
671 671 pIT2 + H5 sequencing primer 3161-3929 Forward GCGTTGTGGTTTGTACTGGT 
672 672 pIT2 + H5 sequencing primer 3161-3929 Reverse GCAGCACCGTAATCAGTAGC 
673 673 pIT2 + H5 sequencing primer 1390-2096 Forward AAGTCGTGTCTTACCGGGTT 
674 674 pIT2 + H5 sequencing primer 1390-2096 Reverse CCGCTCACAATTCCACACAA 
675 675 pIT2 + H5 sequencing primer 2654-3388 Forward AGTCTCCATCCTCCCTGTCT 
676 676 pIT2 + H5 sequencing primer 2654-3388 Reverse GGTTTTGCTCAGTACCAGGC 
677 677 pIT2 + H5 sequencing primer 733-1511 Forward GAGGCGGATAAAGTTGCAGG 
678 678 pIT2 + H5 sequencing primer 733-1511 Reverse CTCAGTTCGGTGTAGGTCGT 
679 H5_gblock_Fwd CTATGACCATGATTACGCCAAGC  
680 H5_gblock_Bck GTGATGGTGATGATGATGTGC  
 
 
RESULTS AND DISCUSSION 
 
Twenty colonies from a bacteria stock expected to contain H5 and its plasmid were 
grown and picked on a M9 minimal medium plate. Picked colonies were expanded at 37 
°C then had their plasmid DNA harvested and sequenced by using the recommended 
Lifesciences primers, 363 and 362. Bacterial stock struggled to grow even at the 
theoretically optimal temperature of 37 °C, thus suggesting cytotoxic effects on cells at 37 
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°C of the scFv.  All of the reads were made up of short (few hundred bases), with extremely 
low Q16 and Q20 scores. Because of such results, a detailed pIT2 sequence was 
hypothesized based on Figure 5 and used to design different primers. Additionally, two 
new stocks of H5 bacteria were identified, one prepared on May 2012 and another on July 
2012. Four cell cultures in SOB were grown at 30 °C to avoid most cytotoxic effects. The 
cultures were dubbed 1 and 2 from the July stock, while 3 and 4 from the May stock. 
Culture tubes 1 and 3 had media supplemented with 1% glucose. Samples were 
amplified after being miniprepperd, by also using a primer derived from the hypothesized 
pIT2, 119. As additional control, TG1 cells expressing a scFv from the Tomlinson I + J 
library targeting ubiquitin (termed Ub), which was expected to share most of the H5 
sequence and pIT2. As a negative control, ready to be infected by phage TG1-Tr cells were 
also used. By using two couples of primers, largely different band sizes were expected, as 




Figure 6: Primers 363 and 119 were used in the first 6 out of 12 reactions. Expected product about 1Kb, 
labeled as S(hort). Primers 363 and 362 were used for the remaining 6 reactions. Product should be 3.5 Kb, 
thus L(ong). H5 colonies were numbered from 1 to 4, the anti-Ubiquitin TG1 strain was labeled Ub and the 
TG1 Tr strain was labeled Tr, Ladder used was 1Kb by NEB 
 
The larger size band (from primers 363, 362) was not visible after running the 0.8% 
agarose gel.  Thus, the four cultures described above were used in larger total volumes (100 
µL) of PCR reactions with primers 119 and 363. While the presence of glucose in media 
had little effect on cell growth and plasmid sequence, the time at which the bacterial stock 
was frozen appears to change results drastically. After excising the 1 kb band (Figure 7), 
purifying the DNA in agarose with a spin column kit (Qiagen), the products were 
sequenced. Unlike samples 1 and 2, samples 3 and 4 from May 2012 returned low quality 





Figure 7: A. The 1kb bright and well defined band (red boxes) was cut out, the agarose dissolved and the 
three samples were sequenced separately. Notice potentially empty vector/construct underneath samples 1, 2 
bands of interest. B. Based on the previous successful extraction, analogous bands were excised. This time 
the bands of interest appear to be less than 1 Kb. The bright and narrow band (red boxes) was cut out, the 
agarose dissolved and the three samples were sequenced separately.  
The poor sequencing results from 3 and 4 cultures raised suspicion about the 
possibility of E. coli altering the DNA sequence of the plasmid in order to avoid cytotoxic 
effects from the scFv being expressed, as described earlier in Chapter 1, thus invalidating 
the whole May stock for H5 recovery purposes. A new PCR amplification set was prepared 
with culture 1 along with the anti-ubiquitin control, which should slightly differ in DNA 
sequence but not in size (number of base pairs). Half of the amplifications would use the 
primer couple 133. 118, which should flank the whole H5 insert, while the couple 141, 118 





Figure 8: Amplified samples of the anti-Ubiquitin scFv and the H5 DNA sequences. For columns (1), 
primers 133 - 118 size were used and the product had an expected size of 940 bp. For columns (2), primers 
141 - 118 were used and expected product size was about 500 bp. Ladder used is 1 kb from NEB.  
 
Since the sizes for each amplification set matched the expectations, the samples 
were excised, cleared from agarose then sequenced. Long, high quality reads shared the 
general consensus developed from the earlier experiments, shown in Appendix A. 
Lastly, several primers (665 to 678) were designed using Primer3 in order to have 
each PCR amplified segment not much longer than 700 bp and roughly 100 bases of 
overlap for redundancy. The resulting products were purified with a spin column kit, then 
sequenced. While the entirety of pIT2 could not be sequenced, we are confident about the 
3000 bp portion obtained, which encompasses the most relevant parts of pIT2 (upstream 






Recovery of the H5 sequence was a non-trivial task because of the lack of 
information on the vector used, pIT2, and the suggested primers unreliability. Furthermore, 
inconsistent in PCR amplification results while using the same set of primers suggested 
heterogeneity in our H5 stocks. A significant portion of the bacteria contained the empty 
pIT2 alone. This is likely due to metabolic processes during the growing phase due to the 
cytotoxicity of the scFv at 37 °C. Despite all these issues, the H5 and pIT2 sequences were 
used as the starting point for the codon optimization and the library creation strategies 
detailed in the following chapters. As an additional consequence of this work, all of the 
bacterial cultures involving pIT2 and H5 derivatives were grown 30 °C to avoid the insert 





OPTIMIZING THE H5 SEQUENCE 
 
Achieving high level of protein expression is a fundamental endeavor of every 
research or industrial project in synthetic biology. More and more often polypeptide and 
protein production rely on synthetic DNA because of the increase in speed and convenience 
of DNA manipulation tools (Newcomb, Carlson, & Aldrich, 2007). Given the redundancy 
of mRNA codons mapped to amino acids, there exist several genes that translate to the 
same protein even within the same organism. Thus, usual strategies to improve protein 
expression focus on mimicking the codon bias of natural highly expressed genes in the host 
of choice. This led to the widespread adoption of the CAI (Sharp & Li, 1987). However, 
while there are several reports of such strategy working out, it is worth noticing that only 
the successful cases are reported in the literature, and those differ greatly from case to case 
in many regards, making it difficult to extrapolate trends that correlate with good levels of 
expression.  
Welch and colleagues attempted to shed some light on the relation between protein 
expression and DNA (mRNA) sequences with a model relying on partial least square 
regression that correlated sequence properties with actual expression of a scFv and a DNA 
polymerase in BL21 DE3 pLysS strain of E. coli (Welch et al., 2009). They concluded that 
while GC bias, runs of C and G, internal Shine-Dalgarno motifs, overrepresentation of 
codon pairs and RNAseE cleavage sites do not correlate with expression levels, while a 
distributed property like codon usage is strongly correlated (Welch et al., 2009). A small 
fraction scFv variants tested showed expression levels well below the model prediction, 
while also showing complex secondary mRNA structure in the first 15 codons. This 
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suggests that deleterious 5’ region motifs or mRNA secondary structure should still be 
accounted for best results (Kudla, Murray, Tollervey, & Plotkin, 2009).  
This work is particularly relevant because the model developed indicates significant 
differences in expression levels for genes designed according to the CAI or by focusing on 
rare codons. It is suggested that the biochemical reason for the success of the latter strategy 
lies in the charging levels of the tRNA isoacceptor (aminoacyl-tRNA) cognate to the 
uncommon codons, defined according to the CAI (Elf et al., 2003).  
Elf et al. work suggests that in cases of amino acid starvation, the rate of codon 
reading (mRNA translation) is affected only by the rates of supply and demand for the 
charged tRNA. Indeed, in the vast majority of cases in which different tRNA read 
synonymous codons, at least one isoacceptor tRNA remained at a high charging level even 
when the rate of cognate amino acid supply approached zero. Thus, this theory formulates 
that charging levels of tRNA isoacceptors will change vastly based on amino acid 
limitations, with the further ramification that reading of so defined rare codons takes place 
at a higher rate when there is almost zero supply of the cognate amino acid.  
The insights from Welch et al. model and experimental evidence were used to 
automatize the codon optimization for genes expressing scFv, polymerases or a generic 
protein to a lesser degree. The routine was written in Matlab (Mathworks) and is reported 




Matlab was used because of the convenience of the prebuilt functions for DNA 
sequence manipulation. The main function allows the user to browse for a file in FASTA 
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format, open it and checks if it contain an amino acid or nucleotide sequence. In the latter 
case, the sequence is translated to amino acids. Then the codon optimizer function is called 
within a for loop, once for every amino acid making up the sequence. Given the modularity 
of the optimizer function, it is possible to change the call line in the main function and 
codon optimize for a specific category of protein, in this case scFv.  
The function reverse-translating amino acids is made up by a switch statement, with 
one case for each amino acid and the stop codon mark. Every time this function is called, 
a random number between 0 and 1 is drawn. Each case statement is structured with 
consecutive if statements, checking if the random number is within an amino acid specific 
set of intervals between 0 and 1. Those intervals were elaborated from the experimental 
data on scFv mutants expressed in the work from Welch et al., which are reported in the 
Supplemental Material (Welch et al., 2009). The variants that showed the highest 
expression levels were tallied in order to build codon frequency tables that reflected the 
theory of rare codons affecting translation rate. This data is also available for the DNA 
polymerase variants investigated and for a combination of the most highly expressed 
variants (Welch et al., 2009). 
After all amino acids are reverse-translated, the main function writes a new FASTA 
file with the optimized sequence. 
 
RESULTS AND DISCUSSION 
 
After recovering the H5 and pIT2 sequences as described in Chapter 2, the scFv 
domains and linker parts of the larger H5 sequence were used as input for the Matlab 
routine, as shown in Appendix A. This was done because the His-tag and the myc-tag were 
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beyond the chosen restriction enzyme sites, SphI towards the 5’ end and NotI towards the 
3’ end (Appendix A). The trimmed H5 sequence was used as the input for the Matlab 
routine five times. Those optimized sequences, while expressing the same amino acids, 
differ in the use of synonymous codon because of the different random number being 
drawn every time the optimizer function was called. The algorithm was implemented this 
way because of the nature of the data available, frequency tables. While there exists a 
sequence that would lead to the best expression among those five, each of them is 
significantly correlated to lead to higher levels of expression as compared to DNA using 
traditional strategies (Welch et al., 2009). 
The five sequences were inspected to avoid strong secondary mRNA structure in 
the first 45 bases (15 codons) or other distributed deleterious motifs like four consecutive 
identical bases (such as 4 G in a row). The chosen sequence is reported in Appendix A. In 
order to make such sequence useful in the library creation procedure, portions of pIT2 to 
include the two tags (at the 3’ end) and the SphI restriction site were added. This DNA 




A short Matlab routine was written to codon optimize DNA sequences for 
expression in BL21 DE3 pLysS. This method relied on the experimental data from Welch 
et al. that was combined in frequency tables. While their work was focused on scFv and 
DNA polymerase, this routine can be adapted to any protein category as long as a codon 
frequency table is provided because of the built-in modularity. 
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A shorter version of the optimized H5 sequence was used as input in for this code 
and was codon optimized. While this program sufficed in its first version for the purposes 
of its work, it could certainly be improved by automating tasks relevant to the determining 
the best DNA sequence for expression, like checking for certain deleterious mRNA motifs. 
Moreover, other studies based on the original work by Welch et al. attempted to improve 
the accuracy of the model predictions by adding more parameters, beyond the codon 
translation under starvation speed patterns (Fernandes & Vinga, 2016). For example, 
Fernandes and Vinga also included free energy of the growing polypeptide in their model. 
While such improvements would yield better predictions on the expressions level of the 
target protein and could be adapted in this code algorithm, the potentially marginal 






ALTERING SPECIFICITY BY INTRODUCING VARIATION IN 
THE H5 SEQUENCE 
 
The methods employed to generate potentially beneficial mutations in the H5 
antibody fragments are described in this section. First, the BL21 DE3 pLysS optimized 
DNA sequence was amplified and mutated through ePCR. Secondly, the mutated inserts 
were ligated into pIT2 using restriction enzymes. Lastly, the new vectors were transformed 
in competent DH5α High Efficiency cells, thus creating stable library ready to undergo 




To achieve a library of mutated clones of H5, the optimized DNA sequence in 
gBlock format was used as the template in ePCR. First, a 50 µL volume control run was 
set up in order to evaluate efficiency of Taq polymerase (from NEB), following the 
protocol provided by the manufacturer. The amplified products were compared with the 
amplification results from a standard PCR run using Phusion polymerase (NEB), also 
following the provided protocol. Both trial runs were cycled on a BioRad Dyad at 94 °C 
for 1 minute, then at 45 °C for 1 minute then at 72 °C for 1 more minute. This cycle was 
repeated 30 times, while no hotstart procedure or final extension step were included 
(Cadwell & Joyce, 1992). Both products were run on a thick 0.8% agarose gel, excised, 
purified then sequenced (Macrogen). For the mutagenic reactions, the protocol from 
Caldwell and Joyce (Cadwell & Joyce, 1992) was adopted with minor variations in order 
to limit bias in base change. Specifically, twelve 50 µL reactions each contained 2.5 units 
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of Taq polymerase, 10 µL of 10X Standard Tag (Magnesium free) buffer (NEB), 20 fmoles 
of H5 template and 30 pmoles of each primer. To increase errors and base substitutions, 7 
mM of magnesium chloride and 0.5 mM manganese chloride were added, while the 
inclusion of 0.2 mM of dATP, dGTP and 2 mM of dTTP and dCTP was aimed to minimize 
the base substitution bias. All of the above aliquots were cycled on a BioRad Dyad as 
described above.  
The mutated products were purified with a PCR spin column kit by Qiagen, eluted 
in EB buffer (Qiagen), then underwent double digestion to expose the “sticky ends” 
necessary for the ligation into the pIT2 plasmid. 10 µg of ePCR purified product was 
incubated for 1 hour at 37 °C along with 40 units of SphI-HF, 40 units of NotI-HF in 
Cutsmart buffer (restriction enzymes and buffers from NEB), in a total reaction volume of 
100 µL. The digested dsDNA was purified with a spin column kit as above.  
The full pIT2 plasmid containing the past H5 insert was underwent double digestion 
as well. After harvesting the entire plasmid from pre-existing H5 stocks grown in SOB 
media via miniprep, 1 µg of the vector was added to 10 units of units of SphI-HF, 10 units 
of NotI-HF in Cutsmart buffer (NEB), in a total reaction volume of 100 µL, for an 
incubation time of 90 minutes at 37 °C. In order to verify the completion of the digestion, 
the products were run on a thick 0.8% agarose gel, excised and purified with the Qiagen 
kit as above.  
The ligation of the mutated inserts in the open pIT2 vector took place immediately 
after. The protocol adopted was partially adapted from You and Zhang (You & Percival 
Zhang, 2012). To ensure high efficiency, 1 µg of mutated inserts and 0.5 µg of the empty 
plasmid were incubated with 1200 units of T4 ligase (NEB) in T4 buffer (NEB) for a total 
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reaction volume of 600 µL. The reagents were added on ice, then the vial was kept at 4 °C 
for 24 hours. After the reaction completed, the newly formed library was purified with a 
PCR purification kit as above.  
Purified plasmids were then transformed into DH5α High Efficiency competent 
cells from NEB, along with the pUC19 control vector, following the provided protocol: 
four aliquots of 50 µL were thawed on ice, then mixed with 5 µL of the purified library (45 
ng of cDNA) each. The four mixtures were kept on ice for 30 minutes, heat shocked at 42 
°C for 30 seconds, placed on ice again for 5 minutes then added to 950 µL of SOC medium 
and incubated at 37 °C for 1 hour while shaking at 250 rpm. The four aliquots were pooled 
then serial dilutions in SOC were used to seed LB agar plates in duplicate (100 µL of 
culture per plate) in order to estimate the library size (Daugherty, Chen, Iverson, & 
Georgiou, 2000). LB medium was supplemented with 100 µg/mL of carbenicillin and 1% 
glucose. The remaining starting culture from the transformation was grown in 100 mL of 
the same LB media to create a large library stock. After 24 hours of growth at 30 °C, 20 
colonies were picked at random from the plates to be grown in LB medium supplemented 
as above, miniprepped and sequenced to estimate the error rate of the library (Daugherty 
et al., 2000).  
 
RESULTS AND DISCUSSION 
 
The products from the regular PCR using Taq and Phusion polymerase respectively 





Figure 9: Products of the control PCR reactions. Left column contains products from Phusion amplification, 
the right products from Taq polymerase and the central column is 1 kb ladder from NEB. The same volume 
of DNA was loaded in each of the wells (4 µL of sample and 1 µL of 6x loading dye). The apparent difference 
in product size can be explained by the not uniform run of the dye (not shown) which implies agarose gel 
artifacts. 
 
The sequencing reaction confirmed that the two products were indeed the H5 
sequence including the restriction sites but without the histidine tag section. Using a 
NanoDrop spectrophotometer after spin column purification and elution in 50 µL of EB 
buffer, the final sample concentrations of the test runs were 25 ng/µL for the Phusion and 
104 ng/µL for the Taq polymerase. These results suggested that Taq polymerase could 
provide a significant amplification of the gBlock used as starting material, even though the 
two yields are not directly comparable due to difference in starting template amounts and 
different definition of enzyme units (NEB website, accessed 20 June 2016). The amount 
of amplified DNA obtained from the test Taq PCR was used to plan the amount of reactions 
and reagents needed to create a sizeable library, as explained in the next paragraph. 
The target library size was chosen to be 105 clones, equivalent to 105 colonies 
forming units (cfu) on an agar plate. Despite the theoretical efficiency of the competent 
cell line, a conservative 105 cfu/µg of DNA efficiency was assumed, thus the required 
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amount of ligated plasmids was 1 µg. The molecular weights of the pIT2 vector with insert, 
empty pIT2 and H5 cloned insert were calculated to be 3.24*106, 2.71*106 and 5.36*105 
g/mol respectively, based on the sequences of the starting samples. Consequently, 3.08*10-
13 moles of ligated pIT2 + insert clones would be needed to create a library of such a size. 
Assuming a ligation efficiency of 10% despite the long reaction time and low temperature 
used, as well as a 10X stoichiometric excess of inserts in the ligation mixtures to drive the 
pIT2+insert ligation instead of other combinations, 3.08*10-12 moles of vector and 3.08*10-
11 moles H5 clones would be required. These amount translate to roughly 8.3 µg and 16.5 
µg of dsDNA respectively. Furthermore, about a four-fold factor was included to account 
for human errors and product loss during the several purification steps, leading to the 
needed amounts of 30 and 60 µg of pIT2 vectors and H5 clones.  
 
Figure 10: agarose gel containing aliquots from the same digestion reaction in three lanes. The size of the 
main band in each H5 lane matches the expected size and the short segments trimmed at the 5’ and 3’ ends 




The High Fidelity versions of the two restriction enzymes were employed in this 
protocol for two reasons: they have maximum efficiency in the same Cutsmart buffer and 
show limited deleterious star activity. These advantages saved time, effort and contributed 
to quality digested products. The digested pIT2 products run on agarose gel confirm the 
size of the empty pIT2 vector along with the H5 insert being excised, as shown by the 
bands below the 1 kbase line in Figure 11.  
 
Figure 11: A. shows the digested pIT2 plasmid from identic reaction vials. The plasmids were first harvested 
from a stock colonies confirmed for expressing the original H5. The band about 1 kb represents the H5 insert, 
now removed. B. shows the shows the digested pIT2 plasmid from identic reaction vials. The plasmids were 
first harvested from a stock colonies expressing the anti-ubiquitin scFv used as control in phage screening. 




The ligated products were also run on an agarose gel to obtain a visual confirmation 
that the main reaction result was the pIT2 plus insert instead of other useless combinations 
like multiple joined vectors or multiple inserts together. 
 
 
Figure 12: Aliquots from the same ligation mix were run on 0.8 % agarose gel to verify the formation of the 
desired products. The green arrowheads indicate two close bands between 5 and 6 kb, the largest of which 
represent the correct pIT2 + H5 insert product, while the other represents empty ligated pIT2. Cyan 
arrowheads indicate the presence of products made up of several joined H5 mutants. Far from obtaining 
100% correct product formation, this gel suggests that the colonies surviving selection in carbenicillin (given 
by pIT2) may or may not express an H5 mutant. 
 
Agar plates seeded after the DH5α transformation were used to estimate the library. 
As shown in Figure 13, colonies grew even on the 10-4 dilution plates. Taking the average 
between the duplicates, it can be safely assumed that the final library size is greater or equal 
than 104 individual mutants (Daugherty et al., 2000). Most of the 20 single colonies that 
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were expanded, miniprepped and sequenced show a comparable plasmid size to the original 
H5. Sequencing results, assembled in Geneious 9.0 (Biomatters Ltd.) showed an average 
mutation rate of 0.358%, as compared to the rate of 0.66% from the source protocol 
(Cadwell & Joyce, 1992). While the adapted protocol used here appears to be less effective 
than its source, a lower mutation rate is not necessarily a negative for this application. 
Indeed, a larger average mutation rate could have led to several mutant clones that 
completely lose functionality, despite their VH and VL sequence, because of relatd amino 
acid mutations in the linker region or the portions conferring structure to the scFv  
 
 
Figure 13: Pictures of transformed DH5α serial dilutions on LB agar plates supplemented with 1% glucose 
and 100 µg/mL carbenicillin, after 24 hours incubation at 30 °C. A. no dilution plate from pooled cell aliquots. 
B. 100-fold dilution plate. C 10000-fold dilution plate, with two colonies. D. 100-fold dilution of control 






The codon optimized H5 was successfully used as a template for an ePCR reaction 
aimed to introduce point mutations in the scFv sequence. The mutated fragments were 
inserted in the original pIT2 vector then transformed in DH5α to ensure plasmid stability 
over time. The library size is estimated to be greater or equal to 104 clones, each with an 
average error rate of 0.358%. The library is now ready to be screened through phage display 
in order to identify an improved version of the H5 probe, used to discern between strained 
and native states of Fn. Screening for a probe for another cryptic ECM protein site is not 






CONCLUSION AND FUTURE DIRECTIONS 
 
After the creation of the library with a diversity of 104, each copy varying by 3 
nucleotides on average (for an average rate of 0.358%), the next steps involve rounds of 
selection in order to distinguish at least 30 clones that show promise in binding the 
stretched Fn conformation fragment, 4G. Afterwards, clone candidates will be sequenced 
and their affinity and selectivity for the 4G fragment will be quantified. Here follow the 
detailed procedures for panning and affinity estimation. 
Aliquots of BL21 DE3 pLysS library will be infected by the helper bacteriophage 
KM13, which is a trypsin sensitive derivative of M13 while growing at OD of in LB media. 
The resulting phages will be enriched by subsequent (usually three) rounds of screening 
against the target molecule, in this case the 9th and 10th type III repeats of Fn. The antigen 
can be biotinylated or physisorbed to the substrate (C. M. Y. Lee et al., 2007) used, whether 
an immuno-tube or simple tissue culture plastic. Given the reliability of the 4G fragment 
as a model for strained Fn, it will be used to screen phage clones, without need of 
biotinylation. After stringent washes, the unbound phages will be removed from 
subsequent screens, then the bound phages will be eluted with trypsin, collected and used 
to infect fresh E. coli. Finally, a blinded double round of ELISA will be used to identify 
the promising phage clones. One 96 well plate will be coated with the 4G fragment, while 
the second will be coated with 9*10, which represents the same Fn type III repeats in their 
canonical configuration. The clones selected will be the ones showing qualitatively strong 
binding to 4G and weak to no binding on 9*10.  
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The selected phages will be sequenced and their binding affinity will be quantified 
through SPR assays. Specifically, a self-assembled monolayer of alkanethiols comprised 
of 20% -COOH and 80% -OH functional groups will be assembled on a BIACORE gold 
sensor chip surface, by incubation of 1mM stock alkanethiol solution on the gold chip 
overnight at room temperature. SPR experiments will be performed on a BIACORE 2000 
instrument. The two Fn fragments will be immobilized on the chip using EDC/sulfo-NHS 
chemistry, while several dilutions of the scFv fragments will be prepared in binding buffer. 
SPR sensograms will be processed with Scrubber software for double referencing, and 
curves will be fit to experimental data using a 2-site heterogeneous surface model using a 
third party software. 
The clone with the largest improvement in binding affinity for Fn and binding 
specificity over the current H5 probe will be transformed for large expression into BL21 
DE3 pLysS strain. The current values for H5 are 16 nM for the strained state, while the KD 
for the relaxed state was 107 nM. Once a system for large scFv is established, competitive 
binding assays will be performed with soluble Fn fragments displaying only either the 9th 
(FnIII6- 9) or 10th (FnIII10- 14) type III repeats, which should indicate that the new H5 
epitope is located within Fn 9III repeat as well (unpublished data).  
Since the improvements achieved thus far would overcome most developmental 
hurdles for delivering and using the antibody for non-invasive imaging of tissue fibrosis, 
the data suggest that the Fn integrin binding mechano-switch is a pathophysiologically 
relevant signature (unpublished data). This system could then provide insights into 
mechanisms of tissue fibrosis. 
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Additionally, recent reports suggests that αv integrins on myofibroblasts are 
implicated for fibrogenesis in a broad range of fibrotic diseases (Henderson et al., 2013), 
and that pharmacological blockade of αv integrins ameliorates liver and lung fibrosis. Past 
standard cell attachment experiments to Fn-adsorbed substrates, which presented multiple 
conformations of Fn due to surface-mediated unfolding, have confirmed the previous H5 
clone selectively inhibits Fn-integrin αvβ3, but not α5β1 interactions with Fn (unpublished 
data). Given that our past H5 antibody version demonstrated such effectiveness in vitro, 
the new H5 would be ready for in vivo studies, bar functionalization to improve circulation 
time and organ targeting. 
Because of all of the above reasons, the new H5 shows even greater potential for 
not only imaging and diagnostic application in fibrosis, but also for targeting therapeutic 






APPENDIX A: H5 SEQUENCES 
 
Legend. Cyan: linker region. Red: restriction sites for SphI and NotI respectively. Yellow: HIS-tag. Green: 
myc-tag. All capitalized nucleotides were used as input for the codon optimization routine described in 
Chapter 3 and reported in Appendix B.  
 


















































APPENDIX B: CODON OPTIMIZATION CODE 
 
% Codon optimizer main. Version 0.1 
% Author: Leandro Moretti 
%  
% Description: function opens a file in XX format, converts it to aa 
% sequence then picks the best codons for E Coli expression according 
to the 
% frequency tables from the work of Welch et al., PLOS one 2009.  
% A new file containing the new DNA sequence is produced.  
%  
% In future versions, new functionality will be added in order to check 
for 












%obtain file name 
title=input('Type complete file name.\nEnsure it''s in same directory 
as this script \n','s'); 
% %opening FASTA file 
sequence=fastaread(char(title),'TrimHeaders',true); 
  
%checking if FASTA file is in aminoacid format 
%(program expects aa sequences to start with M methionine) 
if sequence.Sequence(1)~='M'||'m' 







%calling actual optimizer function 
for i=1:1:n 
    codon=optimscFv(seqAA(i)); 
    %putting new codon together with DNA sequence 




%writing newly found sequence to a new FASTA file 
%NOTE: if this script is run multiple files, the FASTA file is 
appended, 











function [dna] = optimscFv(aa) 
%Function reads an amminoacid and returns EColi optimized codon 
  
% Codons are chosen based on frequency table from Welch et al., PLOS 
one 2009 
% Various amminoacids are sorted through thanks to a case statement 
% Random number generator is reseeded every time the function is 
called. 
% Fnc takes in a string and returns a three letter string 
  
%Leandro Moretti, June 10th 2016 
  








    case {'A','a'} 
        if n<=0.24 
            dna='GCA'; 
        else if n<=43 
                dna='GCC'; 
            else if n<=55 
                    dna='GCT'; 
                else 
                    dna='GCG'; 
                end 
            end 
        end 
%%  
%arginine  
    case {'R','r'} 
        if n<=0.03 
            dna='AGA'; 
        else if n<=0.38 
                dna='CGC'; 
            else 
                dna='CGT'; 
            end 
        end 
%% 
%asparagine 
    case {'N','n'} 
        if n<=0.47 
            dna='AAT'; 
        else 
            dna='AAC'; 
        end 
         
 %% 
 %aspartic acid 
    case {'D','d'} 
        if n<=0.46 
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            dna='GAT'; 
        else 
            dna='GAC'; 
        end 
         
%% 
%cysteine 
    case {'C','c'} 
        if n<=0.42 
            dna='TGT'; 
        else  
            dna='TGC'; 
        end 
         
%% 
%glutamine 
    case {'Q','q'} 
        if n<=0.45 
            dna='CAA'; 
        else 
            dna='CAG'; 
        end 
         
%% 
%glutamic acids 
    case {'E','e'} 
        if n<=0.43 
            dna='GAA'; 
        else 
            dna='GAG'; 




    case {'G','g'} 
        if n<=0.39 
            dna='GGC'; 
        else 
            dna='GGT'; 
        end 
         
%% 
%histidine 
    case {'H','h'} 
        if n<=0.38 
            dna='CAT'; 
        else 
            dna='CAC'; 
        end 
         
%% 
%isoleucine 
    case {'I','i'} 
        if n<=0.49 
            dna='ATT'; 
        else 
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            dna='ATC'; 
        end 
         
%% 
%leucine 
    case {'L','l'} 
        if n<=0.03 
            dna='CTC'; 
        else if n<=0.05 
                dna='CTT'; 
            else if n<=0.08 
                    dna='TTA'; 
                else if n<=0.22 
                        dna='TTG'; 
                    else 
                        dna='CTG'; 
                    end 
                end 
            end 
        end 
         
 %% 
 %lysine 
    case {'K','k'} 
        if n<=0.49 
            dna='AAG'; 
        else 
            dna='AAA'; 
        end 
      
%% 
%methionine 
    case {'M','m'} 
        dna='ATG'; 
         
%% 
%phenylananine 
    case {'F','f'} 
        if n<=0.45 
            dna='TTT'; 
        else 
            dna='TTC'; 
        end 
         
%% 
%proline 
    case {'P','p'} 
        if n<=0.1 
            dna='CCA'; 
        else if n<=0.19 
                dna='CCT'; 
            else 
                dna='CCG'; 
            end 
        end 





    case {'S','s'} 
        if n<=0.02 
            dna='TCA'; 
        else if n<=0.12 
                dna='TCT'; 
            else if n<=0.17 
                    dna='TCG'; 
                else if n<=0.3 
                        dna='TCC'; 
                    else 
                        dna='AGC'; 
                    end 
                end 
            end 
        end 
         
%% 
%threonine 
    case {'T','t'} 
        if n<=0.1 
            dna='ACT'; 
        else if n<=0.43 
                dna='ACG'; 
            else 
                dna='ACC'; 
            end 
        end 
        
%% 
%tryptophane 
    case {'W','w'} 
        dna='TGG'; 
         
%% 
%tyrosine 
    case {'Y','y'} 
        if n<=0.42 
            dna='TAT'; 
        else 
            dna='TAC'; 
        end 
         
%% 
%valine 
    case {'V','v'} 
        if n<=0.03 
            dna='GTA'; 
        else if n<=0.31 
                dna='GTC'; 
            else if n<=0.65 
                    dna='GTG'; 
                else 
                    dna='GTT'; 
                end 
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            end 




    case {'*'} 
        dna='TAG'; 
        %always Amber codon as stop codon 
         
%% 
%end of switch statement 
    otherwise 
        fprintf('undefined amino acid letter/n try again'); 
        dna='XXX'; 
end 
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